CCR2 INHIBITOR CCX140 EFFECTIVE IN PHASE 2 CLINICAL TRIAL IN DIABETIC NEPHROPATHY

被引：0
|
作者：
de Zeeuw, Dick [1 ]
Henkel, Elena [2 ]
Psottova, Jana [3 ]
Paragh, Gyorgy [4 ]
Mehling, Heidrun [5 ]
Hasslacher, Christopher [6 ]
Potarca, Antonia [7 ]
Bekker, Pirow [8 ]
Schall, Thomas J. [9 ]
机构：
[1] Univ Med Ctr Groningen, Clin Pharm & Pharmacol, NL-9713 AV Groningen, Netherlands
[2] Tech Univ Dresden, Diabet, D-01062 Dresden, Germany
[3] Diainmed, Diabet, Prague, Czech Republic
[4] Univ Debrecen, Diabet, Debrecen, Hungary
[5] Free Univ Berlin, Diabet, Berlin, Germany
[6] Heidelberg Univ, Diabet, Heidelberg, Germany
[7] ChemoCentryx, Clin Operat, Mountain View, CA USA
[8] ChemoCentryx, Med & Clin Affairs, Mountain View, CA USA
[9] ChemoCentryx, R&D, Mountain View, CA USA
来源：
NEPHROLOGY DIALYSIS TRANSPLANTATION | 2015年 / 30卷
关键词：
D O I：
10.1093/ndt/gfv195.1
中图分类号：
R3 [基础医学]; R4 [临床医学];
学科分类号：
1001 ; 1002 ; 100602 ;
摘要：
SP457
引用
收藏
页数：1
相关论文
共 50 条
  • [31] EFFECTIVE REDUCTION OF DIABETIC NEPHROPATHY INDUCED ALBUMINURIA WITH SGLT2 INHIBITOR MONOTHERAPY
    Shakoor, Muhammad
    Shah, Ankur
    AMERICAN JOURNAL OF KIDNEY DISEASES, 2021, 77 (04) : 650 - 650
  • [32] Genetic variants of MCP-1 and CCR2 genes and IgA nephropathy risk
    Gao, Jie
    Liu, Xinghan
    Wei, Linting
    Niu, Dan
    Wei, Jiali
    Wang, Li
    Ge, Heng
    Wang, Meng
    Yu, Qiaoling
    Jin, Tianbo
    Tian, Tian
    Dai, Zhijun
    Fu, Rongguo
    ONCOTARGET, 2016, 7 (47) : 77950 - 77957
  • [33] The dual CCR2/CCR5 inhibitor Cenicriviroc ameliorates murine primary biliary cholangitis
    Reuveni, D.
    Leung, P.
    Vig, P.
    Shibolet, O.
    Gershwin, E. M.
    Zigmond, E.
    JOURNAL OF HEPATOLOGY, 2017, 66 (01) : S75 - S76
  • [34] Monocyte/macrophage chemokine receptor CCR2 mediates diabetic renal injury
    Awad, Alaa S.
    Kinsey, Gilbert R.
    Khutsishvili, Konstantine
    Gao, Ting
    Bolton, W. Kline
    Okusa, Mark D.
    AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY, 2011, 301 (06) : F1358 - F1366
  • [35] MONOCYTE/MACROPHAGE CHEMOKINE RECEPTOR CCR2 MEDIATES DIABETIC RENAL INJURY
    Awad, A. S.
    Gao, T.
    INFLAMMATION RESEARCH, 2011, 60 : 73 - 74
  • [36] Targeting the MCP-1/CCR2 System in Diabetic Kidney Disease
    Giunti, Sara
    Barutta, Federica
    Perin, Paolo Cavallo
    Gruden, Gabriella
    CURRENT VASCULAR PHARMACOLOGY, 2010, 8 (06) : 849 - 860
  • [37] Identification of effective CCR2 inhibitors for cancer therapy using humanized mice
    Sugiyama, Shigeaki
    Yumimoto, Kanae
    Fujinuma, Shun
    Nakayama, Keiichi, I
    JOURNAL OF BIOCHEMISTRY, 2024, 175 (02): : 195 - 204
  • [38] ACTION (AT1R AND CCR2 TARGETS FOR INFLAMMATORY NEPHROSIS) PHASE 2A TRIAL FOR FOCAL SEGMENTAL GLOMERULUSCLEROSIS
    Roger, S.
    Packham, D.
    Shephard, R.
    Power, D.
    NEPHROLOGY, 2018, 23 : 78 - 78
  • [39] COMBINED INHIBITION OF CCR2 AND ACE PROVIDES ADDED PROTECTION AGAINST PROGRESSION OF DIABETIC NEPHROPATHY IN NOS3 DEFICIENT MICE
    Tesch, G.
    Pullen, N.
    Nikolic-Paterson, D.
    NEPHROLOGY, 2018, 23 : 21 - 22
  • [40] Combined inhibition of CCR2 and ACE provides added protection against progression of diabetic nephropathy in Nos3-deficient mice
    Tesch, Gregory H.
    Pullen, Nick
    Jesson, Michael, I
    Schlerman, Franklin J.
    Nikolic-Paterson, David J.
    AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY, 2019, 317 (06) : F1439 - F1449
12345